

Human CD30/TNFRSF8 F(ab')2 (Research Grade Brentuximab Biosimilar) Antibody

Recombinant Monoclonal Human IgG₁ Clone # Hu8F2 Catalog Number: MAB11129-FAB2

DESCRIPTION	
Species Reactivity	Human
Specificity	Detects human CD30/TNFRSF8 in direct ELISAs. This non-therapeutic antibody uses the same variable region sequence as the therapeutic antibody Brentuximab. This product is for research use only.
Source	Recombinant Monoclonal Human IgG ₁ Clone # Hu8F2
Purification	Protein A or G purified from cell culture supernatant
Immunogen	Human CD30/TNFRSF8
Formulation	Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied either lyophilized or as a 0.2 μm filtered solution in PBS.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

	Recommended Concentration	Sample
Flow Cytometry	0.25 µg/mL	Jurkat human acute T cell leukemia cell line

DATA		
Flow Cytometry	Betection of CD30/TNFRSF8 in Jurkat human acute T cell leukemia cell line by Flow Cytometry. Jurkat human acute T cell leukemia cell line was stained with Human Anti-Human CD30/TNFRSF8 (Brentuximab Biosimilar) F(ab')2 Monoclonal Antibody (Catalog # MAB11129- FAB2, filled histogram) or no antibody (open histogram) followed by APC-conjugated Anti- Human IgG Secondary Antibody (Catalog # F0135). View our protocol for Staining Membrane- associated Proteins.	
PREPARATION AND S	TORAGE	
Reconstitution	Reconstitute at 0.5 mg/mL in sterile PBS.	
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C	
Stability & Storage	ty & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles. • 12 months from date of receipt, -20 to -70 °C as supplied. • 1 month, 2 to 8 °C under sterile conditions after reconstitution. • 6 months, -20 to -70 °C under sterile conditions after reconstitution.	

BACKGROUND

Brentuximab is a biosimilar directed against the extracellular domain of CD30.

Rev. 7/5/2022 Page 1 of 1



Global bio-techne.com info@bio-techne.com techsupport@bio-techne.com TEL +1 612 379 2956 USA TEL 800 343 7475 Canada TEL 855 668 8722 China TEL +86 (21) 52380373 Europe | Middle East | Africa TEL +44 (0)1235 529449